| abstract |
Ophthalmic formulations containing as an active ingredient 11-(3-dimethylaminopropylidene) -6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof are useful for inhibiting cytokine release (e.g., IL-6 and IL-8) from human ocular cells. Such formulations can be used to treat or prevent ocular neovascularization and non-allergic inflammatory disorders such as dry-eye, keratitis, blepharitis, uveitis and inflammation related to infection. |